Enzyme replacement therapy prevents loss of bone and fat mass in murine homocystinuria
journal contributionposted on 08.03.2019 by Tomas Majtan, Insung Park, Erez M. Bublil, Jan P. Kraus
Any type of content formally published in an academic journal, usually following a peer-review process.
Skeletal and connective tissue defects are the most striking symptoms in patients suffering from
classical homocystinuria (HCU). Here, we determined body composition and bone mass in three
mouse models of HCU and assessed whether a long-term administration of enzyme replacement
therapy (ERT) corrected the phenotype. The mouse models of HCU were analyzed using dualenergy
X-ray absorptiometry and the data were complemented by plasma biochemical profiles.
Both the mouse model lacking CBS (KO) and the one expressing human CBS mutant transgene on
amouse CBS null background (I278T) showed marked bone loss and decreased weight mostly due
to a lower fat content comparedwith negative controls. In contrast, theHOmouse expressing the
human CBS WT transgene on a mouse CBS null background showed no such phenotype despite
similar plasma biochemical profile to the KOand I278T mice.More importantly, administration of
ERT rescued bone mass and changes in body composition in the KO mice treated since birth and
reversed bone loss and improved fat content in the I278T mice injected after the development of
clinical symptoms. Our study suggests that ERT for HCU may represent an effective way of preventing
the skeletal problems in patients without a restricted dietary regime.